Artivion (NYSE:AORT) Price Target Raised to $46.00

Artivion (NYSE:AORT) had its price objective boosted by Stifel Nicolaus from $40.00 to $46.00 in a report published on Monday morning,Benzinga reports. The firm currently has a buy rating on the stock.

AORT has been the topic of a number of other reports. Needham & Company LLC raised their price target on Artivion from $45.00 to $50.00 and gave the company a “buy” rating in a report on Friday, August 22nd. LADENBURG THALM/SH SH lowered shares of Artivion from a “buy” rating to a “neutral” rating and increased their target price for the company from $32.00 to $38.80 in a research report on Wednesday, August 13th. JMP Securities upped their price target on shares of Artivion from $33.00 to $42.00 and gave the stock a “market outperform” rating in a research note on Friday, August 8th. Wall Street Zen upgraded shares of Artivion from a “hold” rating to a “buy” rating in a research note on Monday, August 25th. Finally, Canaccord Genuity Group upped their target price on Artivion from $41.00 to $50.00 and gave the stock a “buy” rating in a research report on Monday. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $43.13.

Artivion Price Performance

NYSE AORT opened at $41.05 on Monday. The company has a 50-day moving average price of $39.98 and a two-hundred day moving average price of $31.73. Artivion has a 52 week low of $21.97 and a 52 week high of $45.07. The stock has a market cap of $1.94 billion, a price-to-earnings ratio of -97.74 and a beta of 1.70. The company has a current ratio of 4.78, a quick ratio of 3.48 and a debt-to-equity ratio of 0.52.

Artivion (NYSE:AORT) last issued its quarterly earnings data on Thursday, August 7th. The company reported $0.24 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.11 by $0.13. Artivion had a positive return on equity of 5.70% and a negative net margin of 4.43%.The business had revenue of $112.97 million during the quarter, compared to the consensus estimate of $107.96 million. Artivion’s quarterly revenue was up 15.3% on a year-over-year basis. Artivion has set its FY 2025 guidance at EPS. Analysts forecast that Artivion will post 0.37 EPS for the current year.

Insider Buying and Selling at Artivion

In other Artivion news, SVP Marshall S. Stanton sold 18,200 shares of Artivion stock in a transaction that occurred on Wednesday, August 27th. The shares were sold at an average price of $44.02, for a total value of $801,164.00. Following the transaction, the senior vice president owned 64,200 shares in the company, valued at approximately $2,826,084. The trade was a 22.09% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, SVP Jean F. Holloway sold 10,000 shares of the company’s stock in a transaction on Monday, August 25th. The shares were sold at an average price of $44.37, for a total value of $443,700.00. Following the completion of the transaction, the senior vice president directly owned 172,129 shares in the company, valued at $7,637,363.73. This represents a 5.49% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 74,858 shares of company stock valued at $3,250,129. 7.60% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Artivion

A number of hedge funds and other institutional investors have recently modified their holdings of AORT. Next Century Growth Investors LLC lifted its position in shares of Artivion by 107.6% in the 1st quarter. Next Century Growth Investors LLC now owns 1,022,775 shares of the company’s stock valued at $25,140,000 after acquiring an additional 530,122 shares in the last quarter. Peregrine Capital Management LLC purchased a new position in Artivion during the 1st quarter worth approximately $7,650,000. Invesco Ltd. grew its position in Artivion by 40.8% during the 2nd quarter. Invesco Ltd. now owns 481,026 shares of the company’s stock worth $14,960,000 after purchasing an additional 139,370 shares in the last quarter. Thornburg Investment Management Inc. acquired a new stake in Artivion during the 1st quarter valued at $3,261,000. Finally, Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in shares of Artivion in the first quarter valued at $3,162,000. Institutional investors and hedge funds own 86.37% of the company’s stock.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.